Showing 481-490 of 650 results for "".
- Unpacking the AAD’s Updated Guidelines for Managing AD With Topical Therapies in Adultshttps://practicaldermatology.com/news/guideline-author-dr-robert-sidbury-talks-to-dermwire-about-the-new-recommendations/2461953/Despite the availability of systemic medication to treat atopic dermatitis (AD), topical treatments remain mainstays, and new ones have come to market in recent years. To keep pace with the changes, the American Academy of Dermatology (AAD) updated its 2014 guidelines for managing atopi
- EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in Chronic Hand Eczemahttps://practicaldermatology.com/news/ema-accepts-leo-pharmas-maa-for-delgocitinib-cream-in-chronic-hand-eczema/2461942/The European Medicines Agency (EMA) has validated LEO Pharma’s marketing authorization application for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).
- Evolus Rolls Out New Branding for Jeuveauhttps://practicaldermatology.com/news/evolus-rolls-out-new-branding-for-jeuveau/2461913/Evolus, Inc. is unveiling its new branding for Jeuveau (prabotulinumtoxinA-xvfs). The new Jeuveau imagery reflects today’s consumers, many of whom are millennials and younger. The “Jeuveau, You See Me” marketing campaign uses inclusive messaging to encourage
- Azitra Adds Barbara Ryan and John Schroer to Board of Directorshttps://practicaldermatology.com/news/azitra-adds-barbara-ryan-and-john-schroer-to-board-of-directors/2461876/Barbara Ryan and John Schroer joined Azitra, Inc.’s board of directors. "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets,
- EMA to Review UCB’s Bimekizumab for HShttps://practicaldermatology.com/news/ema-to-review-ucbs-bimekizumab-for-hs/2461869/The European Medicines Agency (EMA) will reviww UCB’s marketing authorization application for bimekizumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab is an IL-17A and IL-17F inhibitor. The safety and efficacy of bim
- WCD News: Experts Excited About Ornovi’s Next Generation JAK Inhibitorhttps://practicaldermatology.com/news/wcd-news-experts-excited-about-ornovis-next-generation-jak-inhibitor/2461833/Ornovi's OR-101 is a highly selective next generation JAK3-ITK inhibitor with potentially a better safety profile than JAK inhibitors currently on the market, according to a presentation at the 25th World Congress of Dermatology Meeting 2023 in Singapore. Seemal Desa
- Merz Aesthetics to Distribute AccuVein’s Visualization Systemhttps://practicaldermatology.com/news/merz-aesthetics-to-distribute-accuveins-visualization-system/2461829/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio adoption. Bas
- Sol-Gel, Searchlight Pharma Partner to Commercialize TWYNEO and EPSOLAY in Canadahttps://practicaldermatology.com/news/sol-gel-searchlight-pharma-partner-to-commercialize-twyneo-and-epsolay-in-canada/2461764/Israel’s Sol-Gel Technologies, Ltd. and Searchlight Pharma Inc. have signed exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that i
- Lumohs, George Tiemann and Company Join Forces to Distribute Lumohs’ Illuminating Devicehttps://practicaldermatology.com/news/lumohs-george-tiemann-and-company-join-forces-to-distribute-lumohs-illuminating-device/2461747/Nano Surgical is partnering with George Tiemann and Company, to bring Lumohs’ illuminating device to dermatology market. Lumohs is a patented, reusable scalpel handle that provides integrated shadowless illumination of the surgical site. With no light obstructions between th
- Incyte Scores Vitiligo Nod for Opzelura Cream in Europehttps://practicaldermatology.com/news/incyte-scores-nod-for-opzelura-cream-for-vitiligo-in-europe/2461674/The European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The selective JAK1/JAK2 inhibi